Effective CD8
+ T cell responses depend on presentation of a stable peptide repertoire by MHC class I (MHC I) molecules on the cell surface. The overall quality of peptide-MHC I complexes (pMHC I) is determined by poorly understood mechanisms that generate and load peptides with appropriate consensus motifs onto MHC I. In this article, we show that both tapasin (Tpn), a key component of the peptide loading complex, and the endoplasmic reticulum aminopeptidase associated with Ag processing (ERAAP) are quintessential editors of distinct structural features of the peptide repertoire. We carried out reciprocal immunization of wild-type mice with cells from Tpn-or ERAAP-deficient mice. Specificity analysis of T cell responses showed that absence of Tpn or ERAAP independently altered the peptide repertoire by causing loss as well as gain of new pMHC I. Changes in amino acid sequences of MHC-bound peptides revealed that ERAAP and Tpn, respectively, defined the characteristic amino and carboxy termini of canonical MHC I peptides. Thus, the optimal pMHC I repertoire is produced by two distinct peptide editing steps in the endoplasmic reticulum. The Journal of Immunology, 2013, 191: 1547-1555. + T cell responses are critically dependent on presentation of an optimally stable pMHC I repertoire.
To elicit robust CD8
+ T cell responses, we selected peptides entering the Ag presentation pathway to yield high-affinity pMHC I that will persist on the cell surface. In addition to a characteristic length of 8-10 aa, the peptides presented by MHC I on the cell surface are uniquely defined by the presence of conserved consensus motifs. The set of peptides bound by a given MHC I molecule shares conserved amino acids located at discrete positions, called anchor residues, that allow peptide binding to the MHC I (3). Amino acid substitutions at these anchor positions resulted in loss of stable interactions between peptides and MHC I that, in turn, inhibited CD8 + T cell responses. The pool of peptides for MHC I presentation is produced from endogenously synthesized proteins fragmented mainly by the multicatalytic proteasome (4) , as well as other proteases (5, 6 ). These models suggest that cytoplasmic proteolysis is primarily responsible for generating the canonical C termini of antigenic peptides. The intermediate peptide fragments are transported into the ER by the TAP (7) . Upon entering the ER, the peptides encounter the peptide loading complex (PLC) that facilitates loading of optimal peptide onto MHC I (8, 9) . The PLC consists of TAP, the chaperones tapasin (Tpn) and calreticulin, the thiol oxidoreductase ERp57, b 2 -microglobulin, and the MHC I H chain. Among these components, Tpn is critical for the formation and function of the PLC (8) (9) (10) . Tpn interacts directly with TAP, the MHC I H chain, and ERp57, thereby bringing the PLC components together and keeping the empty MHC I close to the source of incoming peptides (9) (10) (11) (12) (13) (14) (15) . Consistent with its central function in the PLC, surface expression of MHC I molecules is profoundly diminished in Tpn-deficient mice (16, 17) and in several MHC I molecules in human cells (9, 18) . Furthermore, the loss of Tpn results in presentation of suboptimal pMHC I (9, 11, 17, (19) (20) (21) (22) . Thus, Tpn is the key mediator of peptide loading in the PLC. Nevertheless, the molecular features of the peptide cargo affected by Tpn remain unknown.
The ER aminopeptidase associated with Ag processing (ERAAP) has emerged as yet another editor of the pMHC I repertoire in the ER (23, 24) . The loss of ERAAP caused profound changes in the pMHC I repertoire relative to wild-type (WT) mice (25) (26) (27) (28) (29) . Analysis of CD8 + T cell responses elicited in WT mice by ERAAPdeficient cells showed that classical as well as nonclassical MHC I presented a distinct, highly immunogenic peptide repertoire (26, 27, 30, 31) . Furthermore, examination of the sequence of presented peptides in ERAAP-deficient cells by mass spectrometry revealed that the peptides were longer, often because of extra N-terminal residues (30) . How ERAAP edits peptides presented by MHC I and whether editing occurs within the PLC is not known. Because Tpn physically brings together PLC components, cells without Tpn lack a functional PLC. We reasoned that the peptide editing events in the PLC might be evident in cells lacking Tpn or ERAAP.
In this study, we analyzed the peptide editing functions of Tpn and ERAAP required for generating the optimal pMHC I repertoire. We examined peptide editing events in cells lacking Tpn or ERAAP. By immunological, biochemical, and molecular analyses, we find that ERAAP and Tpn independently edited the N and C termini of the peptide repertoire presented by MHC I on the cell surface. 
Materials and Methods

Mice
Antibodies
The following Abs used for flow cytometry analysis were purchased from BD Biosciences: anti-H-2K b (AF6-88.5), anti-H-2A b (25-9-17) , anti-CD8a (53-6.7), anti-CD4 (RM4-5), and anti-IFN-g (XMG1.2). Abs CD16/32 (Fc block, clone 93) and anti-H-2D
b (28-14-8) were purchased from eBiosciences. For in vivo depletions, purified anti-NK1.1 Ab (PK136) from BioXcell was used. To block presentation by MHC I to T cell lines, we used the following culture supernatants: anti-H-2K b (5F1. 
Cell lines and DNA constructs
ERAAP and TAP double-deficient (ERAAP 2/2 TAP 2/2 ) fibroblasts were previously reported, and immortalized ERAAP 2/2 Tpn 2/2 fibroblast cell lines were generated in the same manner as previously described (25) . The use and generation of b-galactosidase (lacZ)-inducible T cell hybridomas B3Z, 30NXZ, 1AZ, 11P9Z, LPAZ, 27.5Z, and BEKo8Z have been described elsewhere (25, 31) . Activation of T cell hybridomas was determined by measurement of cleavage of the lacZ substrate chlorophenol redb-D-galactopyranoside (Roche). Splenocytes from indicated mice treated with 200 ng/ml LPS (Sigma) for 14-16 h were used as APCs for T cell hybridomas. The ES-X9[SHL8] construct containing ER-localization sequence followed by N terminally extended antigenic SIINFEHL (SHL8) peptide was previously described (34) .
Peptide extraction and reverse-phase HPLC analysis
The preparation, fractionation, and detection of the peptide extracts has been described previously (34) . In brief, the peptides were eluted from the cells by 10% formic acid, fractionated by reverse-phase HPLC, treated with trypsin, and assayed as described previously. Synthetic peptides were prepared by D. King (University of California at Berkeley).
Immunizations and CTL lines
To generate T cell lines, we immunized female Tpn-deficient or WT mice i.p. with 2 3 10 7 spleen cells from male WT or Tpn-deficient mice, respectively. Ten days after immunization, spleen cells were restimulated in vitro. Cultures contained 20 U/ml (first two restimulations) or 50 U/ml (subsequent restimulations) hIL-2 (BD Biosciences) and irradiated spleen cells from female mice of the same genotype used for immunization. Additional restimulations were done every 7-10 d.
Measurement of intracellular IFN-g production by CTLs
The CD8 + T cell responses of the immunized mice were measured by assessment of intracellular IFN-g production. Spleen cell APCs were treated with 200 ng/ml LPS (Sigma) overnight, and CD4 + and CD8 + cells were depleted using magnetic beads (Dynal Biotech, Invitrogen) before incubation with restimulated CD8 + T cells. A total of 1 ml/ml brefeldin A (BfA; GolgiPlug [BD Biosciences]) was added after 1 h, and total incubation of CD8 + T cells and APCs was 5 h. Cells were stained for surface markers followed by intracellular staining for IFN-g. Cells were analyzed by flow cytometry using an LSR II (BD) and with FlowJo Software (TreeStar). All plots were first gated on live cells based on forward/side scatter, followed by gating on CD8 + and IFN-g + . For blocking of particular MHC I molecules, APCs were first incubated for 30 min on ice with Ab supernatant before addition of CD8 + T cells as described earlier. For analysis of pMHC I surface stability, APCs were incubated for 2 or 4 h at 37˚C in medium containing 8 mg/ml BfA (Sigma) followed by addition of CD8 + T cells and staining as described earlier.
In vivo cytotoxicity assay Large-scale peptide sequencing by tandem mass spectrometry
Peptide sequencing using immunoaffinity purification of pMHC complexes from detergent-solubilized spleen lysates was performed as reported previously (35) . In brief, freshly isolated spleen cells from 25 C57BL/6 and 50 Tpn-deficient mice were lysed and pMHC I was immuno-purified using mAbs Y3 (anti-H-2K b ) and B22.249 (anti-H-2D b ). Samples were subject to fast protein liquid chromatography-HPLC fractionation, and sequence identification by nanochip electrospray ionization-quadrupole time of flight mass spectrometer. Peptides were identified with high confidence using an initial search with Spectrum Mill algorithm followed by expert manual spectral validation (36) . To analyze the amino acid conservation of groups of more than seven peptides, we used WebLogo program (http:// weblogo.berkeley.edu/).
Results
ERAAP and Tpn differentially influence pMHC I repertoire
ERAAP and Tpn are both ER-resident editors of the peptide repertoire presented by MHC I. To assess the relative contributions of ERAAP and Tpn to the overall peptide repertoire, we measured pMHC I surface expression by flow cytometry (Fig. 1A-C ERAAP affected pMHC I presentation differentially (23, 25, 31) , ranging from no detectable change in the pK b ligand recognized by the 27.5Z hybridoma to an almost complete loss of the pMHC I ligands recognized by the LPAZ and 11p9Z hybridomas. In contrast, presentation of pMHC I ligands recognized by 1AZ, 30NXZ, and BEko8Z hybridomas was markedly enhanced on surface of ERAAP-deficient cells. In contrast, loss of Tpn was generally deleterious for all the pMHC I ligands tested. Taken together, these observations show that normal expression of pMHC I was influenced by ERAAP and even more so by Tpn.
Absence of Tpn causes selective loss of pMHC I ligands
To further define the specific changes that occurred in the pMHC I repertoire because of loss of Tpn, we took advantage of the immune systems' ability to detect differences between self and nonself. If certain pMHC I were absent in Tpn-deficient mice, specific CD8 + T cells would not be tolerized to them and would respond to the novel pMHC I expressed by WT cells. We immunized Tpn 2/2 mice with WT spleen cells expressing the normally diverse pMHC I repertoire. After 10 d, splenocytes from recipient mice were restimulated for a week with WT spleen cells. The cultures were then analyzed for presence of CD8 + T cells that produced IFN-g when stimulated with spleen cell APCs of the indicated genotype. The Tpn 2/2 anti-WT CD8 + T cells responded strongly to WT APCs but not to self APCs (Fig. 3A, 3B) , showing that Tpn-deficient mice perceived normal pMHC I as foreign in WT cells. We infer that Tpn deficiency caused the loss of many pMHC I normally present in WT cells. Typical of peptides presented by MHC I, these pMHC I required TAP for their presentation (Fig. 3B) .
To establish the ligand specificity of the responding CD8 + T cells, we used spleen cells from K (Fig. 3B) .
Tpn-deficient cells also express novel immunogenic pMHC I
To determine whether loss of Tpn editing also resulted in presentation of novel pMHC I, we immunized WT mice with Tpn 2/2 cells. , but not to self WT APCs, indicating presence of novel pMHC I in Tpn 2/2 cells (Fig. 4A, 4B) .
Tpn expression appears to affect TAP stability and could thus influence peptide transport into the ER (37). Therefore, it was possible that the peptides presented in the absence of Tpn could be independent of TAP transport (38, 39 precursors in the presence or absence of WT ERAAP. The peptides extracted from transfected cells were fractionated by HPLC to separate the untrimmed precursor from the trimmed peptide products. The HPLC fractions were assayed for presence of antigenic peptides containing SHL8 with or without the N-terminal extension using the SHL8/K b -specific B3Z hybridoma as described earlier (34) . In ERAAP 2/2 TAP 2/2 cells without ERAAP (vector alone), the N-terminally extended precursor peptide was the predominant peptide species (Fig. 5A, upper panel) . Upon coexpression of ERAAP, the precursor peptide was no longer detected, and two peaks corresponding to the precisely cleaved SHL8 octapeptide and the KSHL8 nonapeptides were found (Fig.  5A, lower panel) . The SHL8 and KSHL8 peptides, respectively, represent the final products presented by the K b and D b MHC I present in these cells. Likewise, the same precursor and processed peptides were detected in presence or absence of ERAAP in Tpndeficient cells (Fig. 5B) . Thus, in the ER, ERAAP could trim antigenic precursors to their final products in the absence of TAP or Tpn. The results show directly that expression of either TAP or Tpn, and therefore an intact PLC, is not required for N-terminal trimming of antigenic precursors by ERAAP.
Tpn-and ERAAP-deficient cells express unique, nonoverlapping pMHC I
To further assess the relationship between peptide editing by ERAAP and Tpn, we examined the potential overlap between novel peptides generated in the absence of Tpn or ERAAP. T cell lines generated in WT mice by immunization with Tpn or ERAAPdeficient cells were tested for responses to various APCs. The Tpn 2/2 anti-WT CD8 + T cell lines responded to both WT and ERAAP 2/2 APCs equally well, suggesting that both cells presented the unique pMHC I that were lost in Tpn 2/2 mice (Fig.   6A ). In contrast, the WT anti-Tpn 2/2 lines recognized only Tpndeficient cells but did not recognize either WT or ERAAP 2/2 cells (Fig. 6B) . Likewise, WT anti-ERAAP 2/2 lines recognized ERAAP
2/2
APCs but did not respond to either WT or Tpn 2/2 APCs (Fig. 6C ).
The lack of cross-reactivity between T cells specific for Tpn 2/2 or ERAAP 2/2 APCs showed that ERAAP and Tpn have distinct and nonoverlapping roles in editing peptides for presentation on MHC I. To further rigorously establish the distinction between the immunologically distinct Tpn or ERAAP-dependent ligands, we target cells in vivo (Fig. 7) . We primed WT mice with splenocytes from ERAAP 2/2 , Tpn 2/2 , or WT mice as a negative control.
Seven days later, the mice were challenged with a cell mixture containing an equal number of WT, ERAAP 2/2 , and Tpn
spleen cells as targets (Fig. 7A, 7B ). We depleted NK cells in host mice before immunization and challenge to obviate the possible effect of these cells in targeting Tpn 2/2 or ERAAP 2/2 cells with lower MHC I expression (17, 40) . To distinguish the three populations of donor cells recovered from host animals in vivo, we labeled each target cell population with a different fluorescent dye as shown schematically (Fig. 7A) . After 20 h, spleens from host WT mice were analyzed for the presence of each labeled cell population (Fig. 7B, output) . A decrease in the percentage of cells recovered relative to the WT (self) targets indicates elimination of individual populations by the immune system of WT hosts. T cell lines demonstrates that the unedited peptide repertoires in cells deficient in ERAAP versus Tpn were distinct without any detectable overlap.
Tpn-deficient cells present peptides lacking canonical consensus motif
The earlier findings showed that loss of Tpn results in the presentation of a novel set of peptides on the cell surface that are im- , respectively. We did not find any obvious differences in the intracellular localization of the source proteins for these peptides (data not shown). Many peptides in Tpn 2/2 -deficient splenocytes were also found in WT mice (Fig. 8A, Supplemental Fig. 1A , Supplemental Tables I, II) . Remarkably, comparison of the unique peptides in Tpn 2/2 cells with their WT counterparts revealed significant differences. First, peptides in Tpn 2/2 cells were markedly longer than those in WT cells (Fig. 8B, Supplemental Fig. 1B) . Second, the canonical asparagine (N) residue at the p5 position of D b bound peptides was consistently absent in peptides produced in absence of Tpn (Fig. 8C, 8D) . A loss of the conserved phenylalanine or tyrosine residues (F/Y) at the p5 anchor position was less obvious in peptides bound to K b (Supplemental Fig. 1C, 1D ). The most striking difference in the amino acid sequences was found in the C-terminal (PV) position of K b and D b peptides eluted from Tpn 2/2 samples. Typically, the C-terminal position is occupied by an aliphatic amino acid: Met (M), Ile (I), Leu (L), or Val (V), as seen in peptides found in WT cells (Fig. 8C, 8D , Supplemental Fig. 1C, 1D ). However, in the Tpn 2/2 samples, a higher frequency of abnormal amino acids was identified at PV. These included Lys (K), Ser (S), Asn (N), Pro (P), and Ala (A) for D b (Fig. 8C, 8D ), and Thr (T) and Pro (P) for K b (Supplemental Fig.  1C, 1D) . Thus, the ability to choose the appropriate C-terminal amino acid, a key determinant of pMHC I stability, was lost in the absence of Tpn.
We 
Discussion
We show in this article that generation of the optimal pMHC I repertoire required independent editing by Tpn and ERAAP. were highly specific and did not cross-react. Amino acid sequences of unedited peptides revealed that differences between the peptides in ERAAP versus Tpn-deficient cells were in their Nand C-terminal anchor residues, respectively. Thus, Tpn defines the C terminus, whereas ERAAP shapes the N terminus of canonical MHC I peptides. The MHC I molecules present an extraordinarily diverse set of peptides to allow effective immune surveillance of virtually all endogenous proteins (3). Nevertheless, the canonical peptides presented by a given MHC I molecule share certain key features: a length of 8-10 aa, and the presence of conserved residues at the C terminus and at an internal p2 or p5 position (41) . These conserved amino acids are called anchor residues because their presence determines the stability of the pMHC I (42) . Editing of the available peptide repertoire is crucial to ensure that only the stable pMHC I reach the surface that are capable of triggering CD8 + T cell responses. To generate the optimal pMHC I repertoire thus requires the editing mechanisms to determine the appropriate C termini, the length, as well as the internal conserved residues. The extent to which these choices are determined by the shape of the peptide binding groove of the MHC I itself versus other key players in the pathway has remained unclear. The MHC I molecules are loaded with their peptide cargo in the ER within the PLC (8) . The crucial role of the PLC in peptide loading has been demonstrated by the severe loss of peptideloaded MHC in cells without Tpn (16, 17) . Tpn is the key element that holds the PLC together and retains the MHC I molecules in the ER until loaded with appropriate peptides (43) . When various antigenic peptides were assessed for binding MHC I in the ER and subsequent display on the cell surface, presentation efficiency was determined by peptide affinity in presence of Tpn, but not other PLC components (20) . Likewise, through in vitro reconstitution in microsomes, Tpn mediated the binding of high-affinity peptide to MHC I (44) . Taken together with the severe reduction of pMHC I expression on the surface when Tpn was lost, these observations suggest that most peptides require editing in the PLC. Which structural aspects of the canonical MHC I-bound peptides determined the appropriate affinity threshold remained unclear.
We first used an immunological approach to characterize the changes in the peptide repertoire caused by loss of Tpn. We elicited CD8 + T cell responses in WT mice immunized with spleen cells from Tpn-deficient mice and vice versa. Because the immune response has evolved to distinguish nonself from self, the CD8 + T cell responses are exquisitely specific for nonself pMHC I. Importantly, the T cell can reveal changes in the pMHC I repertoire caused by alterations in Tpn expression that are not readily detected by any other assay. The specificity of the CD8 + T cell responses showed that the absence of Tpn, like that of ERAAP described earlier (26) , caused the loss of many WT pMHC I, as well as gain of other immunogenic pMHC I. As in ERAAPdeficient cells, the new pMHC I expressed by Tpn-deficient cells were also less stable, suggesting that the presented peptides were structurally distinct from their WT counterparts.
Interestingly, different structural changes in the pMHC I repertoire were caused by the loss of Tpn rather than by loss of ERAAP. We compared the effects of ERAAP versus Tpn deficiency to determine whether there were similarities in their editing functions. To examine a broad set of endogenous pMHC I, we compared the potential cross-reactivity of WT CD8 + T cells responses elicited by Tpn versus ERAAP-deficient cells. We did not detect crossreactivity between the two groups, suggesting that the unedited peptide repertoires of ERAAP2/2 and Tpn2/2 cells did not overlap. The lack of overlap between pMHC I generated in absence of ERAAP or Tpn was also found in vivo, ruling out potential artifacts caused by in vitro cultures. Although both ERAAP2/2 and Tpn2/2 unedited pMHC I were potently immunogenic and caused in vivo rejection, mice primed with Tpn2/2 did not reject ERAAP2/2 targets and vice versa. Independent analysis of naturally processed peptides extracted from living cells further confirmed that ERAAP function did not require Tpn or the peptide transporter, TAP. Together, these results strongly support the notion that Tpn and ERAAP edit different aspects of the pMHC I repertoire.
Mass spectrometry analysis of peptides eluted from ERAAP and Tpn-deficient spleen cells revealed the molecular basis for the structural differences in the unedited pMHC I repertoires. In the absence of Tpn, the most striking changes occurred at the C terminus where noncanonical amino acids at PV were far more frequent than in WT cells. In contrast, many more K b and D b bound peptides in ERAAP-deficient splenocytes were extended by extra amino acids at the N terminus or by potential bulges between the anchor residues, but the C termini always contained the canonical residues (30) . Appropriate C-terminal anchor residues could therefore be maintained in presence of Tpn in ERAAP-deficient cells, but generation of the appropriate N termini required ERAAP. Thus, Tpn was important not only for integrity of the PLC, but also for its unique role in editing the C termini of peptides presented by MHC I.
Previous studies have assumed that cytosolic enzymes, such as the proteasome, generated peptides with canonical C-terminal residues (4, 45) . However, our data showed that Tpn is the ultimate arbitrator for ensuring that peptides with appropriate Cterminal residue are presented. Consistent with a role for Tpnmediated editing at the C termini of peptides, T134K mutation in the a2 helix of MHC I was found to affect Tpn-MHC I interactions in human cells (46) . Although the molecular mechanism by which Tpn edits peptides is still unclear, putative models for peptide optimization via Tpn include accelerated dissociation of unfavorable peptides (40, 44, 47) or maintenance of the MHC I in a peptide-receptive conformation until bound by a high-affinity peptide (48) . Notably, Tpn-MHC interactions occurred with the C-terminal end of the MHC I peptide binding groove.
In conclusion, Tpn and ERAAP edit distinct aspects of the peptides loaded onto MHC I molecules in the ER and explain the canonical features of the MHC I peptide cargo. Because the changes in pMHC I ligands due to failure of these editing steps are nonoverlapping, it should be interesting to determine why Tpn or ERAAP are differentially targeted for immune evasion by viruses (49) (50) (51) and in cancer (40, 52) .
